Results 31 to 40 of about 407,619 (292)

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?

Journal of Market Access & Health Policy, 2020
Background: Limited previous research and guidelines on the design of economic evaluation for biosimilars have led to unresolved methodological questions on how to assess biosimilars.
Evelien Moorkens, Hannah Broux, Isabelle Huys, Arnold G. Vulto, Steven Simoens   +4 more
doaj   +1 more source

A Case Study of an Agency\u27s Three Family Preservation Contracts [PDF]

, 2002
This article presents a case study of a nonprofit child welfare agency that delivered family preservation services under three different purchase-of-service (POS) contracts.
Ezell, Mark
core   +1 more source

Feasibility and Tolerability of Performing Portable MRI for Neurological Disorders in an Outpatient Neurology Clinic: A Prospective Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Accessing brain magnetic resonance imaging (MRI) can be challenging, especially for underserved patients, which may lead to disparities in neurological diagnosis. Method This mixed‐methods study enrolled adults with one of four neurological disorders: mild cognitive impairment or dementia of the Alzheimer type, multiple sclerosis ...
Maya L. Mastick, Nomin Enkhtsetseg, Joseph Sadok, Matheus Mochetti, Annabel Sorby Adams, Jennifer Guo, Cristina Trapaga Hacker, Isabella Gomez Hjerthen, Seungwon Lee, Siddharth Satish, Andrew S. Ham, Justin Hill, Denis Balaban, Kevin Kyle, Rebecca L. Gillani, Marcelo Matiello, Aleksandar Videnovic, Eric C. Klawiter, W. Taylor Kimberly, Farrah J. Mateen   +19 more
wiley   +1 more source

Affordable and equitable access to subsidised outpatient medicines? Analysis of co-payments under the Additional Drug Package in Kyrgyzstan

International Journal for Equity in Health, 2019
Background Out-of-pocket (OOP) payments can constitute a major barrier for affordable and equitable access to essential medicines. Household surveys in Kyrgyzstan pointed to a perceived growth in OOP payments for outpatient medicines, including those ...
Sabine Vogler, Peter Schneider, Guillaume Dedet, Hanne Bak Pedersen   +3 more
doaj   +1 more source

Pricing of orphan drugs in oncology and rare diseases

Journal of Market Access & Health Policy, 2020
Objective: The objective of this paper is to determine an upper price limit for an orphan drug by taken a broader perspective and, including also other monetary and non-monetary values for the society.
Mark Nuijten, Stefano Capri
doaj   +1 more source

The relationship of drug reimbursement with the price and the quality of pharmaceutical innovations [PDF]

, 2005
This paper studies the strategic interaction between pharmaceutical firms' pricing decisions and government agencies' reimbursement decisions which discriminate between patients by giving reimbursement rights to patients for whom the drug is most ...
García-Alonso, M. D. C., Mariñoso, B. G.   +1 more
core  

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications [PDF]

, 2019
© 2019 Salek, Lussier Hoskyn, Johns, Allen and Sehgal. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).This analysis follows our recent study showing that Canadian public reimbursement delays
Adcock, Balasubramanian, Bertozzi, Bruce, Cave, Curtis, Hazell, Jeffcott, Milliken, Millson, Navarria, O’Connor, Pessina, Russo, Salek, von Elm   +15 more
core   +3 more sources

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Understanding the adoption of new drugs decided by several stakeholders in the South Korean market: a nonparametric event history analysis

Health Economics Review, 2018
Background Regulatory approval and reimbursement decisions are necessary if new drugs are to become accessible in a timely manner. However, the process of regulatory approval and the establishment of reimbursement decisions varies across countries.
Kyung-Bok Son
doaj   +1 more source